- Intralesional or intramuscular administration of a recombinant bivalent human papillomavirus (HPV) vaccine (Ceravix) appears effective for the treatment of patients with multiple recalcitrant common warts.
Why this matters
- Warts are often recalcitrant to common treatments, necessitating new options.
- 81.8% of patients treated with intralesional bivalent HPV vaccine and 63.3% of patients treated with intramuscular bivalent HPV vaccine achieved complete clearance (P=.287).
- The clearance rate was faster in the intralesional group compared with the intramuscular group (3.22 vs 4.57 months; P=.005).
- All patients reported tolerable pain at the injection site.
- Localized itching was reported in 90.9% of the intralesional group and 95.5% of the intramuscular group.
- No recurrences were reported during a 6-month follow-up.
- 44 patients with recalcitrant multiple common warts (>2 years duration with no response to ≥2 treatment modalities), 22 who received intralesional bivalent HPV vaccine and 22 who received intramuscular bivalent HPV vaccine, were included.
- Funding: None.
- Small sample size.
- No control group.